[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654028":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":13,"centralContacts":13,"locations":13,"responsibleParty":28,"collaborators":13,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":13,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":13,"enrollmentInfo":41,"targetDuration":13,"studyType":44,"phases":13,"briefSummary":45,"conditions":46,"keywords":50,"overallStatus":58,"whyStopped":13,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":13},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Serum Asprosin Level","Serum asprosin concentration (measured in ng\u002FmL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.","Baseline",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_CONTROL","CROSS_SECTIONAL","Adult patients aged 18 years and older diagnosed with rheumatoid arthritis fulfilling the 2010 ACR\u002FEULAR classification criteria, recruited from the inpatient and outpatient clinics of the Rheumatology, Rehabilitation, and Physical Medicine Department at Assiut University Hospital, along with age- and sex-matched healthy control individuals.",[19,22,25],{"label":20,"type":13,"description":21,"interventionNames":13},"Rheumatoid Arthritis with Metabolic Syndrome","Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR\u002FEULAR classification criteria who also meet the NCEP ATP III criteria for metabolic syndrome (presence of 3 or more metabolic components). Serum Asprosin levels and cardiometabolic risk indices will be evaluated.",{"label":23,"type":13,"description":24,"interventionNames":13},"Rheumatoid Arthritis without Metabolic Syndrome","Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR\u002FEULAR classification criteria who do not meet the NCEP ATP III diagnostic criteria for metabolic syndrome. Serum Asprosin levels and cardiometabolic risk indices will be evaluated.",{"label":26,"type":13,"description":27,"interventionNames":13},"Healthy Controls","Age- and sex-matched healthy control individuals without rheumatoid arthritis, metabolic syndrome, or systemic inflammatory conditions, recruited for comparative assessment of baseline serum Asprosin levels.",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Viola Rafaat Shafik Tadros","Resident of Rheumatology, Rehabilitation and Physical medicine","100654028","serum-asprosin-metabolic-syndrome-and-cardiometabolic-risk-in-rheumatoid-arthritis-100654028",false,"NCT07793747","Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis","Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR\u002FEULAR classification criteria.\n* Ability and willingness to provide written informed consent.\n* Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.\n\nExclusion Criteria:\n\n* Presence of other autoimmune diseases or overlap syndromes.\n* Active acute or chronic infectious diseases.\n* Pregnancy or lactation.\n* Current malignancy or previous history of malignancy.\n* Severe hepatic or renal impairment.\n* Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.","ALL","18 Years",{"count":42,"type":43},75,"ESTIMATED","OBSERVATIONAL","Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood.\n\nThe purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices).\n\nParticipants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.",[47,48,49],"Rheumatoid Arthritis","Metabolic Syndrome","Cardiovascular Diseases",[51,52,53,54,55,56,57],"Asprosin","Cardiometabolic Risk","DAS28","Adipokines","Atherogenic Index of Plasma","Triglyceride-Glucose Index","Insulin Resistance","NOT_YET_RECRUITING","2026-08-26",{"date":61,"type":62},"2026-08-31","ACTUAL",{"date":64,"type":43},"2026-10",{"date":66,"type":43},"2027-11",{"name":5,"class":6}]